FDA Approves Strattera(R) For Maintenance Of ADHD In Children And Adolescents

ADHD often fascinates me as far as whether is is totally a genetic condition that can be diagnosed, or is is sometimes a "learned" behavior in today's world...or is it accelerated due to the deluge of information we are handling as humans today...I guess whatever the diagnosis could be, there's help on the way with Strattera...which is a non stimulant...something new from what has been on the market to date. BD

Eli Lilly and Company (NYSE: LLY) announced that the United States Food and Drug Administration (FDA) has approved Strattera(R) (atomoxetine HCI) for maintenance treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approved non-stimulant to treat ADHD in children, adolescents and adults.
"The approval provides physicians and their patients with the first treatment option that is indicated for maintenance of ADHD" said Thomas J. Spencer, M.D., Associate Professor of Psychiatry, Harvard Medical School. "This is critical as ADHD may be a life-long disease and effective long-term control of symptoms may mean improved outcomes in children and adolescents."